1. Dual hypoxia-responsive supramolecular complex for cancer target therapy
- Author
-
Jian-Shuang Guo, Juan-Juan Li, Ze-Han Wang, Yang Liu, Yu-Xin Yue, Hua-Bin Li, Xiu-He Zhao, Yuan-Jun Sun, Ya-Hui Ding, Fei Ding, Dong-Sheng Guo, Liang Wang, and Yue Chen
- Subjects
Science - Abstract
Abstract The prognosis with pancreatic cancer is among the poorest of any human cancer. One of the important factors is the tumor hypoxia. Targeting tumor hypoxia is considered a desirable therapeutic option. However, it has not been translated into clinical success in the treatment of pancreatic cancer. With enhanced cytotoxicities against hypoxic pancreatic cancer cells, BE-43547A2 (BE) may serve as a promising template for hypoxia target strategy. Here, based on rational modification, a BE prodrug (NMP-BE) is encapsulated into sulfonated azocalix[5]arene (SAC5A) to generate a supramolecular dual hypoxia-responsive complex NMP-BE@SAC5A. Benefited from the selective load release within cancer cells, NMP-BE@SAC5A markedly suppresses tumor growth at low dose in pancreatic cancer cells xenograft murine model without developing systemic toxicity. This research presents a strategy for the modification of covalent compounds to achieve efficient delivery within tumors, a horizon for the realization of safe and reinforced hypoxia target therapy using a simple approach.
- Published
- 2023
- Full Text
- View/download PDF